Healthcare


 Earnings Surge and Valuation Concerns: A Closer Look at PolyNovo’s Performance

Earnings Surge and Valuation Concerns: A Closer Look at PolyNovo’s Performance

February 25, 2025 01:56 PM AEDT| By Team Kalkine Media

Highlights,PolyNovo,(,ASX:PNOV,) shares,drop,14.7% in early trading.,First-half results show a,strong,increase in net profit and revenue.,Revised forecasts reflect challenges from currency and market pressures.,PolyNovo (ASX:PNOV), a leading medical...

 Nanosonics Limited (ASX:NAN): A Closer Look at Recent Stock Activity

Nanosonics Limited (ASX:NAN): A Closer Look at Recent Stock Activity

February 25, 2025 01:37 PM AEDT| By Team Kalkine Media

Highlights,Nanosonics shares surge 26% in the past month,The company's P/S ratio stands at 7.7x, above industry norms,Future revenue growth aligns closely with industry expectations,Nanosonics Limited, with the ticker (ASX:NAN), has experienced a rem...

 Cryosite's First Half 2025 Financials: A Detailed Look

Cryosite's First Half 2025 Financials: A Detailed Look

February 25, 2025 01:37 PM AEDT| By Team Kalkine Media

Highlights,Cryosite's revenue rises 3.7% to AU$6.64m.,Net income remains steady at AU$838.0k.,Shares increase by 14% in the past week.,The recent financial release by Cryosite (ASX:CTE) for the first half of 2025 reveals a 3.7% increase in revenue, a...

 Firebrick Pharma (ASX:FRE) First Half 2025 Financial Overview

Firebrick Pharma (ASX:FRE) First Half 2025 Financial Overview

February 25, 2025 01:33 PM AEDT| By Team Kalkine Media

Highlights,Significant revenue drop to AU$197.1k from 1H 2024.,Net loss increased by 61% from the previous year.,Shares gained a slight increase over the past week.,The financial landscape of Firebrick Pharma (ASX:FRE) for the First Half of 2025 reve...

 Next Science's stock drops following an FDA warning letter suggesting that their product might have led to injuries.

Next Science's stock drops following an FDA warning letter suggesting that their product might have led to injuries.

February 25, 2025 12:30 PM AEDT| By Team Kalkine Media

Highlights,FDA warning led to a 13% drop in Next Science shares.,Quality system and reporting issues were identified.,Misleading marketing practices raised compliance concerns.,The biotechnology sector is a dynamic and innovative industry, focused on...

 Cambium sees a 43% surge following FDA approval for Phase 3 trial of Elate Ocular.

Cambium sees a 43% surge following FDA approval for Phase 3 trial of Elate Ocular.

February 25, 2025 12:30 PM AEDT| By Team Kalkine Media

Highlights,FDA-approved Phase 3 trial for an innovative ocular therapy.,Nearly 800 participants enrolled across multiple countries.,Potential to transform treatment for moderate to severe dry eye disease.,In the competitive landscape of biotechnology...

 Aroa's Sheep-Derived Products Reach Milestone with Seven Million Medical Uses

Aroa's Sheep-Derived Products Reach Milestone with Seven Million Medical Uses

February 25, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,Aroa Biosurgery’s soft-tissue regeneration products have been used in medical procedures worldwide, surpassing a major usage milestone.,The company’s extracellular matrix technology, derived from New Zealand sheep rumen, continues to advan...

 EZZ Life Science Expands into US Market with Key Manufacturing Deal

EZZ Life Science Expands into US Market with Key Manufacturing Deal

February 25, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,EZZ Life Science enters agreement with GLSP Inc to manufacture dietary supplements in the US, aligning with FDA and ISO-certified standards.,The partnership facilitates EZZ's plan for US market entry in H2 FY25, ensuring improved productio...

 Beamtree Holdings reported a loss of AU$0.011 per share for the first half of 2025, consistent with the AU$0.011 loss per share recorded in the first half of 2024.

Beamtree Holdings reported a loss of AU$0.011 per share for the first half of 2025, consistent with the AU$0.011 loss per share recorded in the first half of 2024.

February 24, 2025 07:38 PM AEDT| By Team Kalkine Media

Highlights:,Revenue increased to AU$14.2 million, reflecting an upward trend from the prior year.,Net loss expanded to AU$3.25 million, while the loss per share remained unchanged.,The share price has declined over the past week.,Beamtree Holdings, l...

 Cogstate (ASX:CGS) Reports Strong Financial Results for First Half 2025

Cogstate (ASX:CGS) Reports Strong Financial Results for First Half 2025

February 24, 2025 01:32 PM AEDT| By Team Kalkine Media

Cogstate (ASX:CGS) Reports Strong Financial Results for First Half 2025

 Cochlear Limited (ASX:COH) Unpacking Financial Strength and Insider Confidence

Cochlear Limited (ASX:COH) Unpacking Financial Strength and Insider Confidence

February 24, 2025 01:32 PM AEDT| By Team Kalkine Media

Cochlear Limited (ASX:COH) Unpacking Financial Strength and Insider Confidence

 INOVIQ's Intriguing First Half 2025 Financial Trajectory

INOVIQ's Intriguing First Half 2025 Financial Trajectory

February 24, 2025 01:30 PM AEDT| By Team Kalkine Media

INOVIQ's Intriguing First Half 2025 Financial Trajectory

 FDA Boosts Neuren Pharmaceuticals (ASX:NEU) with Rare Pediatric Designation

FDA Boosts Neuren Pharmaceuticals (ASX:NEU) with Rare Pediatric Designation

February 24, 2025 01:14 PM AEDT| By Team Kalkine Media

Highlights:,FDA grants rare pediatric designation.,Neuren,Pharmaceuticals (,ASX:NEU,) posts notable gains.,PRV program opens potential new opportunities.,In a remarkable morning session on the ASX 200, Neuren Pharmaceuticals (ASX:NEU) marked a signif...

 Regis Healthcare's Remarkable Turnaround and Expansion Strategy

Regis Healthcare's Remarkable Turnaround and Expansion Strategy

February 24, 2025 12:59 PM AEDT| By Team Kalkine Media

Highlights:,Revenue grew by 17.5%,this,half-year.,Shift from a loss to a net profit.,Expansion through strategic acquisitions.,Regis Healthcare Limited (ASX:REG) delivered a compelling half-year performance ending 31 December 2024, reflecting a stron...

 Perpetual Ends Talks with KKR, Plans Independent Sale of Wealth Management Unit

Perpetual Ends Talks with KKR, Plans Independent Sale of Wealth Management Unit

February 24, 2025 11:11 AM AEDT| By Team Kalkine Media

Highlights,Deal Terminated:,Perpetual ends talks with,KKR,for the sale of wealth management and corporate trust units.,Shareholder Interests:,An independent review found the,revised deal terms were not beneficial,to shareholders.,Sale Still on the Ta...

 Monitor Cryosite as Insider Stock Sales Reach AU$8.3 Million

Monitor Cryosite as Insider Stock Sales Reach AU$8.3 Million

February 23, 2025 03:34 PM AEDT| By Team Kalkine Media

Highlights:,Cryosite Limited shares experienced a notable increase recently.,Insider transactions over the past year reflect more sales than purchases.,Insiders maintain a strong ownership presence in the company.,Cryosite Limited (ASX:CTE) operates...

 Nanosonics Reports Strong Growth in First-Half Financial Results

Nanosonics Reports Strong Growth in First-Half Financial Results

February 23, 2025 03:32 PM AEDT| By Team Kalkine Media

Highlights:,Revenue Growth:,Nanosonics posted a significant increase in revenue, reflecting continued expansion in the medical equipment sector.,Profitability Gains:,The company achieved a notable rise in net income, supported by an improved profit m...

 Health Check: Limited Visits to the GP as Patients Continue to Avoid Appointments Post-COVID

Health Check: Limited Visits to the GP as Patients Continue to Avoid Appointments Post-COVID

February 23, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,Australian Clinical Labs (ASX:ACL),experiences fluctuations in GP and pathology visits, impacting financial outcomes.,EZZ Life Science (ASX:EZZ),expands its market presence with new product launches and broader distribution strategies.,Vit...

 This Hearing-Aid Company is Well-Adapted to a Changing, Competitive Market

This Hearing-Aid Company is Well-Adapted to a Changing, Competitive Market

February 23, 2025 11:00 AM AEDT| By Team Kalkine Media

Highlights,Cochlear (ASX:COH) faces slowed sales of Nucleus 8 processors, prompting a strategic focus on innovation and market expansion.,The company sees promising growth opportunities in emerging markets and the adult and senior segments, despite e...

 Vita Life Sciences Limited (ASX:VLS) Shares Need Better Earnings to Stabilize

Vita Life Sciences Limited (ASX:VLS) Shares Need Better Earnings to Stabilize

February 22, 2025 11:39 AM AEDT| By Team Kalkine Media

Highlights:,Vita Life Sciences maintains a P/E ratio below many companies in the Australian market.,The company has demonstrated consistent earnings growth over multiple years.,Current market sentiment reflects a cautious stance despite strong financ...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.